High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer
Overtreatment is a major concern in patients with prostate cancer (PCa). Prognostic biomarkers discriminating indolent from aggressive disease in prostate biopsy are urgently needed. We aimed to evaluate the prognostic value of Ki67, EZH2, LSD1, and SMYD3 immunoexpression in diagnostic biopsies from...
Gespeichert in:
| Veröffentlicht in: | Urologic oncology 2018-04, Vol.36 (4), p.161.e7-161.e17 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 161.e17 |
|---|---|
| container_issue | 4 |
| container_start_page | 161.e7 |
| container_title | Urologic oncology |
| container_volume | 36 |
| creator | Lobo, João Rodrigues, Ângelo Antunes, Luís Graça, Inês Ramalho-Carvalho, João Vieira, Filipa Quintela Martins, Ana Teresa Oliveira, Jorge Jerónimo, Carmen Henrique, Rui |
| description | Overtreatment is a major concern in patients with prostate cancer (PCa). Prognostic biomarkers discriminating indolent from aggressive disease in prostate biopsy are urgently needed. We aimed to evaluate the prognostic value of Ki67, EZH2, LSD1, and SMYD3 immunoexpression in diagnostic biopsies from a cohort of PCa patients with long term follow-up.
A series of 189 consecutive prostate biopsies diagnosed with PCa (1997–2001) in a cancer center was included in the study, with follow-up last updated in November 2016. Biopsies were reviewed and graded according to 2016 WHO criteria. Immunohistochemistry was performed in the most representative block. Nuclear staining was assessed using digital image analysis. Study outcomes included disease-specific, disease-free, and progression-free survival. Statistical analysis was tabulated using SPSS version 22.0. Survival curves and hazard ratios (HRs) were estimated using Kaplan-Meyer and Cox-regression models, respectively. Statistical significance was set at P |
| doi_str_mv | 10.1016/j.urolonc.2017.10.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1969931866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143917305653</els_id><sourcerecordid>1969931866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-9ae281c73bd26e69c2d6009c90ac1c385657bde922811c9832e7858a224c2d9f3</originalsourceid><addsrcrecordid>eNqFUctuFDEQtBCIhMAngHzkkFncnlk_TgiFwCKCOAAHuFheuzfxasaejD2E_ES-Ga92A8dc3FZXdZddRchLYAtgIN5sF_OU-hTdgjOQtbdgXD0ix6Bk2_BOi8f1zqRqoGv1EXmW85Yx6BTAU3LENchOAhyTu1W4vKJhGOaY8M84Yc4hRZo29HMQ8pSe_1rxU2qjp9--_Hzf0hCpD_YyplyCo-NUqy1I1yGNOWCuuMcR6xFLf1tx9MGVTNNcXBpwNz7aEiqa6U0oV_83OBsdTs_Jk43tM7441BPy48P597NVc_H146ezdxeN6zoojbbIFTjZrj0XKLTjXjCmnWbWgWvVUizl2qPmlQVOq5ajVEtlOe8qVW_aE_J6v7fqX8-YixlCdtj3NmKaswEttG5BCVGpyz3V1afmCTdmnMJgp1sDzOyiMFtziMLsoti1axR17tVBYl4P6P9N3XtfCW_3BKwf_R1wMtlVZ1y1bEJXjE_hAYm_18uetg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1969931866</pqid></control><display><type>article</type><title>High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer</title><source>Elsevier ScienceDirect Journals</source><creator>Lobo, João ; Rodrigues, Ângelo ; Antunes, Luís ; Graça, Inês ; Ramalho-Carvalho, João ; Vieira, Filipa Quintela ; Martins, Ana Teresa ; Oliveira, Jorge ; Jerónimo, Carmen ; Henrique, Rui</creator><creatorcontrib>Lobo, João ; Rodrigues, Ângelo ; Antunes, Luís ; Graça, Inês ; Ramalho-Carvalho, João ; Vieira, Filipa Quintela ; Martins, Ana Teresa ; Oliveira, Jorge ; Jerónimo, Carmen ; Henrique, Rui</creatorcontrib><description>Overtreatment is a major concern in patients with prostate cancer (PCa). Prognostic biomarkers discriminating indolent from aggressive disease in prostate biopsy are urgently needed. We aimed to evaluate the prognostic value of Ki67, EZH2, LSD1, and SMYD3 immunoexpression in diagnostic biopsies from a cohort of PCa patients with long term follow-up.
A series of 189 consecutive prostate biopsies diagnosed with PCa (1997–2001) in a cancer center was included in the study, with follow-up last updated in November 2016. Biopsies were reviewed and graded according to 2016 WHO criteria. Immunohistochemistry was performed in the most representative block. Nuclear staining was assessed using digital image analysis. Study outcomes included disease-specific, disease-free, and progression-free survival. Statistical analysis was tabulated using SPSS version 22.0. Survival curves and hazard ratios (HRs) were estimated using Kaplan-Meyer and Cox-regression models, respectively. Statistical significance was set at P<0.05.
The proportion of patients who completed the study was 177/189 (94%). In univariable analysis, high Ki67, EZH2, and SMYD3 immunoexpression associated with significantly worse disease-specific survival (HR = 1.86, 95% CI: 1.05–3.29; HR = 1.87, 95% CI: 1.10–3.27; HR = 2.68, 95% CI: 1.02–7.92). In multivariable analysis, the 3 biomarkers displayed significantly worse DSS adjusted for CAPRA score (HR = 1.78, 95% CI: 1.01–3.16; HR = 1.93, 95% CI: 1.12–3.32; HR = 2.71, 95% CI: 1.04–7.10). Among patients with low/intermediate risk CAPRA score, high Ki67 immunoexpression identified those more prone to experience disease recurrence (HR = 9.20, 95% CI: 1.27–66.44) and progression (HR = 2.97, 95% CI: 1.05–8.43).
High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with PCa, at diagnosis. This might assist in discriminating indolent from aggressive PCa, improving treatment selection.
•New biomarkers needed for discriminating indolent from aggressive prostate cancer.•High Ki67, EZH2, and SMYD3 independently predict patient outcome in prostate biopsy.•This might aid clinicians in defining therapeutic strategies.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2017.10.028</identifier><identifier>PMID: 29174711</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biopsy ; EZH2 ; Ki67 ; Prognosis ; Prostate cancer ; SMYD3</subject><ispartof>Urologic oncology, 2018-04, Vol.36 (4), p.161.e7-161.e17</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-9ae281c73bd26e69c2d6009c90ac1c385657bde922811c9832e7858a224c2d9f3</citedby><cites>FETCH-LOGICAL-c441t-9ae281c73bd26e69c2d6009c90ac1c385657bde922811c9832e7858a224c2d9f3</cites><orcidid>0000-0003-3171-4666 ; 0000-0001-6829-1391</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2017.10.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29174711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lobo, João</creatorcontrib><creatorcontrib>Rodrigues, Ângelo</creatorcontrib><creatorcontrib>Antunes, Luís</creatorcontrib><creatorcontrib>Graça, Inês</creatorcontrib><creatorcontrib>Ramalho-Carvalho, João</creatorcontrib><creatorcontrib>Vieira, Filipa Quintela</creatorcontrib><creatorcontrib>Martins, Ana Teresa</creatorcontrib><creatorcontrib>Oliveira, Jorge</creatorcontrib><creatorcontrib>Jerónimo, Carmen</creatorcontrib><creatorcontrib>Henrique, Rui</creatorcontrib><title>High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>Overtreatment is a major concern in patients with prostate cancer (PCa). Prognostic biomarkers discriminating indolent from aggressive disease in prostate biopsy are urgently needed. We aimed to evaluate the prognostic value of Ki67, EZH2, LSD1, and SMYD3 immunoexpression in diagnostic biopsies from a cohort of PCa patients with long term follow-up.
A series of 189 consecutive prostate biopsies diagnosed with PCa (1997–2001) in a cancer center was included in the study, with follow-up last updated in November 2016. Biopsies were reviewed and graded according to 2016 WHO criteria. Immunohistochemistry was performed in the most representative block. Nuclear staining was assessed using digital image analysis. Study outcomes included disease-specific, disease-free, and progression-free survival. Statistical analysis was tabulated using SPSS version 22.0. Survival curves and hazard ratios (HRs) were estimated using Kaplan-Meyer and Cox-regression models, respectively. Statistical significance was set at P<0.05.
The proportion of patients who completed the study was 177/189 (94%). In univariable analysis, high Ki67, EZH2, and SMYD3 immunoexpression associated with significantly worse disease-specific survival (HR = 1.86, 95% CI: 1.05–3.29; HR = 1.87, 95% CI: 1.10–3.27; HR = 2.68, 95% CI: 1.02–7.92). In multivariable analysis, the 3 biomarkers displayed significantly worse DSS adjusted for CAPRA score (HR = 1.78, 95% CI: 1.01–3.16; HR = 1.93, 95% CI: 1.12–3.32; HR = 2.71, 95% CI: 1.04–7.10). Among patients with low/intermediate risk CAPRA score, high Ki67 immunoexpression identified those more prone to experience disease recurrence (HR = 9.20, 95% CI: 1.27–66.44) and progression (HR = 2.97, 95% CI: 1.05–8.43).
High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with PCa, at diagnosis. This might assist in discriminating indolent from aggressive PCa, improving treatment selection.
•New biomarkers needed for discriminating indolent from aggressive prostate cancer.•High Ki67, EZH2, and SMYD3 independently predict patient outcome in prostate biopsy.•This might aid clinicians in defining therapeutic strategies.</description><subject>Biopsy</subject><subject>EZH2</subject><subject>Ki67</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>SMYD3</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFUctuFDEQtBCIhMAngHzkkFncnlk_TgiFwCKCOAAHuFheuzfxasaejD2E_ES-Ga92A8dc3FZXdZddRchLYAtgIN5sF_OU-hTdgjOQtbdgXD0ix6Bk2_BOi8f1zqRqoGv1EXmW85Yx6BTAU3LENchOAhyTu1W4vKJhGOaY8M84Yc4hRZo29HMQ8pSe_1rxU2qjp9--_Hzf0hCpD_YyplyCo-NUqy1I1yGNOWCuuMcR6xFLf1tx9MGVTNNcXBpwNz7aEiqa6U0oV_83OBsdTs_Jk43tM7441BPy48P597NVc_H146ezdxeN6zoojbbIFTjZrj0XKLTjXjCmnWbWgWvVUizl2qPmlQVOq5ajVEtlOe8qVW_aE_J6v7fqX8-YixlCdtj3NmKaswEttG5BCVGpyz3V1afmCTdmnMJgp1sDzOyiMFtziMLsoti1axR17tVBYl4P6P9N3XtfCW_3BKwf_R1wMtlVZ1y1bEJXjE_hAYm_18uetg</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Lobo, João</creator><creator>Rodrigues, Ângelo</creator><creator>Antunes, Luís</creator><creator>Graça, Inês</creator><creator>Ramalho-Carvalho, João</creator><creator>Vieira, Filipa Quintela</creator><creator>Martins, Ana Teresa</creator><creator>Oliveira, Jorge</creator><creator>Jerónimo, Carmen</creator><creator>Henrique, Rui</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3171-4666</orcidid><orcidid>https://orcid.org/0000-0001-6829-1391</orcidid></search><sort><creationdate>20180401</creationdate><title>High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer</title><author>Lobo, João ; Rodrigues, Ângelo ; Antunes, Luís ; Graça, Inês ; Ramalho-Carvalho, João ; Vieira, Filipa Quintela ; Martins, Ana Teresa ; Oliveira, Jorge ; Jerónimo, Carmen ; Henrique, Rui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-9ae281c73bd26e69c2d6009c90ac1c385657bde922811c9832e7858a224c2d9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biopsy</topic><topic>EZH2</topic><topic>Ki67</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>SMYD3</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lobo, João</creatorcontrib><creatorcontrib>Rodrigues, Ângelo</creatorcontrib><creatorcontrib>Antunes, Luís</creatorcontrib><creatorcontrib>Graça, Inês</creatorcontrib><creatorcontrib>Ramalho-Carvalho, João</creatorcontrib><creatorcontrib>Vieira, Filipa Quintela</creatorcontrib><creatorcontrib>Martins, Ana Teresa</creatorcontrib><creatorcontrib>Oliveira, Jorge</creatorcontrib><creatorcontrib>Jerónimo, Carmen</creatorcontrib><creatorcontrib>Henrique, Rui</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lobo, João</au><au>Rodrigues, Ângelo</au><au>Antunes, Luís</au><au>Graça, Inês</au><au>Ramalho-Carvalho, João</au><au>Vieira, Filipa Quintela</au><au>Martins, Ana Teresa</au><au>Oliveira, Jorge</au><au>Jerónimo, Carmen</au><au>Henrique, Rui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>36</volume><issue>4</issue><spage>161.e7</spage><epage>161.e17</epage><pages>161.e7-161.e17</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>Overtreatment is a major concern in patients with prostate cancer (PCa). Prognostic biomarkers discriminating indolent from aggressive disease in prostate biopsy are urgently needed. We aimed to evaluate the prognostic value of Ki67, EZH2, LSD1, and SMYD3 immunoexpression in diagnostic biopsies from a cohort of PCa patients with long term follow-up.
A series of 189 consecutive prostate biopsies diagnosed with PCa (1997–2001) in a cancer center was included in the study, with follow-up last updated in November 2016. Biopsies were reviewed and graded according to 2016 WHO criteria. Immunohistochemistry was performed in the most representative block. Nuclear staining was assessed using digital image analysis. Study outcomes included disease-specific, disease-free, and progression-free survival. Statistical analysis was tabulated using SPSS version 22.0. Survival curves and hazard ratios (HRs) were estimated using Kaplan-Meyer and Cox-regression models, respectively. Statistical significance was set at P<0.05.
The proportion of patients who completed the study was 177/189 (94%). In univariable analysis, high Ki67, EZH2, and SMYD3 immunoexpression associated with significantly worse disease-specific survival (HR = 1.86, 95% CI: 1.05–3.29; HR = 1.87, 95% CI: 1.10–3.27; HR = 2.68, 95% CI: 1.02–7.92). In multivariable analysis, the 3 biomarkers displayed significantly worse DSS adjusted for CAPRA score (HR = 1.78, 95% CI: 1.01–3.16; HR = 1.93, 95% CI: 1.12–3.32; HR = 2.71, 95% CI: 1.04–7.10). Among patients with low/intermediate risk CAPRA score, high Ki67 immunoexpression identified those more prone to experience disease recurrence (HR = 9.20, 95% CI: 1.27–66.44) and progression (HR = 2.97, 95% CI: 1.05–8.43).
High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with PCa, at diagnosis. This might assist in discriminating indolent from aggressive PCa, improving treatment selection.
•New biomarkers needed for discriminating indolent from aggressive prostate cancer.•High Ki67, EZH2, and SMYD3 independently predict patient outcome in prostate biopsy.•This might aid clinicians in defining therapeutic strategies.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29174711</pmid><doi>10.1016/j.urolonc.2017.10.028</doi><orcidid>https://orcid.org/0000-0003-3171-4666</orcidid><orcidid>https://orcid.org/0000-0001-6829-1391</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1439 |
| ispartof | Urologic oncology, 2018-04, Vol.36 (4), p.161.e7-161.e17 |
| issn | 1078-1439 1873-2496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1969931866 |
| source | Elsevier ScienceDirect Journals |
| subjects | Biopsy EZH2 Ki67 Prognosis Prostate cancer SMYD3 |
| title | High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A51%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20immunoexpression%20of%20Ki67,%20EZH2,%20and%20SMYD3%20in%20diagnostic%20prostate%20biopsies%20independently%20predicts%20outcome%20in%20patients%20with%20prostate%20cancer&rft.jtitle=Urologic%20oncology&rft.au=Lobo,%20Jo%C3%A3o&rft.date=2018-04-01&rft.volume=36&rft.issue=4&rft.spage=161.e7&rft.epage=161.e17&rft.pages=161.e7-161.e17&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2017.10.028&rft_dat=%3Cproquest_cross%3E1969931866%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1969931866&rft_id=info:pmid/29174711&rft_els_id=S1078143917305653&rfr_iscdi=true |